20 Recruiting Leukemia Phase 2 Clinical Trials
Active phase 2 studies for leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Leukemia studiesPhase 2 Studies for Leukemia
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
📍 The Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland
View Study & Checklist ➔A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
📍 Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of Revumenib and Mezigdomide in People With Leukemia
📍 City of Hope Cancer Center (Data collection only) — Duarte, California
View Study & Checklist ➔A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Checklist ➔